A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Background: To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies. Patients and methods: Entry criteria for the 36 patients i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: von Mehren, M., Schilder, R. J., Cheng, J. D., Temmer, E., Cardoso, T. M., Renshaw, F. G., Bayever, E., Zannikos, P., Yuan, Z., Cohen, R. B.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2008
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2598415/
https://ncbi.nlm.nih.gov/pubmed/18497430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn363
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares